Multidrug Resistant Tuberculosis Completed Phase 1 Trials for Digoxin (DB00390)

Back to Multidrug Resistant Tuberculosis

Also known as: MDR-TB / MDR Tuberculosis / Multidrug-Resistant Tuberculosis / Tuberculosis, Multidrug Resistant / Tuberculosis, MDR / MDR TB / Multi Drug Resistant Tuberculosis / Tuberculosis, Multidrug-Resistant / Multi-Drug Resistant Tuberculosis / TB Multi-drug Resistant / Multidrug resistant tuberculosis (disorder) / Tuberculosis / Tuberculosis (disorder) / Tuberculosis NOS / Tuberculosis NOS (disorder) / Infection TBC / Infection tuberculosis / Infection caused by Mycobacterium tuberculosis (disorder) / TB / Tuberculous (disorder) / Tuberculous (qualifier value) / Tuberculous infections

Indication	Status	Phase
DBCOND0041129 (Multidrug Resistant Tuberculosis)	Completed	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT05526911	A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults	Treatment	Digoxin (DB00390) Dolutegravir (DB08930) Lamivudine (DB00709) Midazolam (DB00683) Tenofovir disoproxil (DB00300)